Opendata, web and dolomites

OXIGENATED SIGNED

Hemoglobin based Protein Nanocarriers for Tumour Oxygenation and a more effective Photodynamic Therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OXIGENATED project word cloud

Explore the words cloud of the OXIGENATED project. It provides you a very rough idea of what is the project "OXIGENATED" about.

content    material    exchanging    training    photosensitizer    scientists    generate    surface    self    stage    therapies    environments    tumour    skin    vivo    skills    oxygen    breast    ultimately    radical    cancer    simultaneous    molecule    coating    multidisciplinary    hemoglobin    causing    photodynamic    peptides    argentina    drug    albumin    core    computer    thailand    precipitation    molecular    networking    actively    generation    germany    homing    molecules    gathered    forefront    serum    photosensitizing    complexed    brazil    commercialization    emission    cells    species    assembly    pdt    nanocarriers    vitro    team    spain    carriers    estonia    intracellular    exposed    hobcs    ros    tested    physics    nano    carbonates    seconded    prepared    death    entrapped    bovine    complementary    malignant    hypoxia    efficiency    mice    tissue    single    participation    secondments    submicron    sme    limited    biology    imaging    efficient    co    therapy    toxicity    radiolabeled    modified    drawback    fate    treatment    tomography    transport    science    scientific    chemistry    delivered    positron    models    oxigenated    fundamental   

Project "OXIGENATED" data sheet

The following table provides information about the project.

Coordinator
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE 

Organization address
address: PASEO MIRAMON 182, PARQUE TECNOLOGICO DE SAN SEBASTIAN EDIFICIO EMPRESARIAL C
city: SAN SEBASTIAN
postcode: 20009
website: www.cicbiomagune.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 920˙000 €
 EC max contribution 920˙000 € (100%)
 Programme 1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
 Code Call H2020-MSCA-RISE-2018
 Funding Scheme MSCA-RISE
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2023-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE ES (SAN SEBASTIAN) coordinator 529˙000.00
2    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 211˙600.00
3    TARTU ULIKOOL EE (TARTU) participant 156˙400.00
4    Surflay Nanotec GmbH DE (BERLIN) participant 23˙000.00
5    CHULALONGKORN UNIVERSITY TH (BANGKOK) partner 0.00
6    FUNDACAO UNIVERSIDADE DE BRASILIA BR (BRASILIA DF) partner 0.00
7    UNIVERSIDAD NACIONAL DE GENERAL SAN MARTIN AR (SAN MARTIN BUENOS AIRES) partner 0.00
8    UNIVERSIDAD NACIONAL DEL SUR AR (BAHIA BLANCA) partner 0.00

Map

 Project objective

A major drawback of Photodynamic Therapy (PDT) and other therapies for cancer treatment is the limited oxygen content, hypoxia, in tumour tissue. In PDT a photosensitizing molecule is delivered to malignant tissue to generate radical oxygen species (ROS). The presence of oxygen is fundamental for ROS generation, ultimately causing the death of tumour cells. This project aims to develop hemoglobin drug delivery nanocarriers in the nano and submicron range for simultaneous oxygen and photosensitizer delivery to tumour tissue for a more efficient Photodynamic Therapy. Hemoglobin-based nanocarriers (HOBCs) will be prepared by co-precipitation of hemoglobin with carbonates and surface coating with bovine serum albumin. The carriers will transport oxygen complexed to hemoglobin while photosensitizer molecules will be entrapped in the core. Carriers will be modified with homing peptides to target them to cancer cells. In vitro studies will be conducted to study the uptake of HOBCs by cells, their intracellular fate, toxicity, and oxygen and photosensitizer delivery. In vivo fate of carriers will be studied in mice with radiolabeled carriers by Positron Emission Tomography and Single Emission Computer Tomography. The efficiency of the HOBCs for oxygen delivery and for PDT will be tested in vitro and in vivo in breast and skin cancer models. A multidisciplinary team has been gathered with scientists at the forefront of Material Science, Self assembly, Physics, Chemistry, Imaging, Molecular Biology and Cancer Therapy from Germany, Estonia, Spain, Brazil, Argentina and Thailand. The participation of a SME will be fundamental for the future commercialization of project developments. OXIGENATED will actively work towards exchanging skills and knowledge through secondments of Early Stage and Experienced Researchers, and through networking and training activities. Seconded researchers will develop new scientific and complementary skills while exposed to new research environments.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OXIGENATED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OXIGENATED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.3.)

EXPLOR (2020)

EXperimentation and simulation based PLatform for beyond 5G Optical-wireless network Research and development

Read More  

EM4FIT (2020)

Entrepreneurial Management for Fostering Innovation and Talents

Read More  

GreenX4Drug (2019)

Green Enantioselective Halogenation for Drug Discovery and Manufacture

Read More